This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.
This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions. 1. Detection of unknown adverse drug reactions 2. Incidence of adverse drug reactions under actual use conditions of the drug 3. Factors that may affect the safety or effectiveness "Safety specification" Thrombotic events, Infusion reaction, re-bleeding
Study Type
OBSERVATIONAL
Enrollment
300
Incidence of adverse drug reactions, Incidence of safety specifications, Incidence of adverse drug reactions by patient background factor
Incidence of adverse drug reactions, Incidence of safety specifications, Incidence of adverse drug reactions by patient background factor
Time frame: 30days
AstraZeneca Clinical Study Information Center
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Aichi, Japan
WITHDRAWNResearch Site
Aichi, Japan
ACTIVE_NOT_RECRUITINGResearch Site
Aichi, Japan
NOT_YET_RECRUITINGResearch Site
Akita, Japan
WITHDRAWNResearch Site
Aomori, Japan
WITHDRAWNResearch Site
Aomori, Japan
ACTIVE_NOT_RECRUITINGResearch Site
Chiba, Japan
ACTIVE_NOT_RECRUITINGResearch Site
Chiba, Japan
WITHDRAWNResearch Site
Ehime, Japan
ACTIVE_NOT_RECRUITINGResearch Site
Ehime, Japan
WITHDRAWN...and 75 more locations